Harbor Capital Advisors Inc. Has $4.20 Million Holdings in Boston Scientific Co. (NYSE:BSX)

Harbor Capital Advisors Inc. raised its position in Boston Scientific Co. (NYSE:BSX) by 2.5% during the fourth quarter, Holdings Channel reports. The firm owned 47,023 shares of the medical equipment provider’s stock after purchasing an additional 1,153 shares during the period. Harbor Capital Advisors Inc.’s holdings in Boston Scientific were worth $4,200,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of BSX. Private Advisor Group LLC lifted its stake in Boston Scientific by 9.8% in the second quarter. Private Advisor Group LLC now owns 35,059 shares of the medical equipment provider’s stock valued at $2,700,000 after buying an additional 3,143 shares during the period. Wedbush Securities Inc. bought a new position in Boston Scientific during the second quarter worth $251,000. Andra AP fonden acquired a new stake in Boston Scientific in the second quarter worth $29,000. MGO One Seven LLC increased its stake in Boston Scientific by 101.5% in the second quarter. MGO One Seven LLC now owns 16,672 shares of the medical equipment provider’s stock valued at $1,284,000 after purchasing an additional 8,399 shares in the last quarter. Finally, LPL Financial LLC raised its holdings in shares of Boston Scientific by 6.4% during the second quarter. LPL Financial LLC now owns 1,015,687 shares of the medical equipment provider’s stock valued at $78,218,000 after purchasing an additional 61,350 shares during the period. 89.07% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on BSX shares. TD Cowen raised their target price on Boston Scientific from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Thursday, December 12th. Bank of America boosted their price objective on Boston Scientific from $90.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, October 22nd. JPMorgan Chase & Co. increased their target price on Boston Scientific from $100.00 to $110.00 and gave the stock an “overweight” rating in a report on Monday, December 16th. Deutsche Bank Aktiengesellschaft upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 price target for the company in a research note on Friday. Finally, Royal Bank of Canada raised their price objective on shares of Boston Scientific from $95.00 to $98.00 and gave the company an “outperform” rating in a research note on Thursday, October 24th. Three research analysts have rated the stock with a hold rating, twenty have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $97.26.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 14,010 shares of the stock in a transaction on Monday, November 25th. The stock was sold at an average price of $89.27, for a total transaction of $1,250,672.70. Following the sale, the executive vice president now owns 978 shares in the company, valued at $87,306.06. This represents a 93.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP John Bradley Sorenson sold 4,119 shares of Boston Scientific stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $90.02, for a total value of $370,792.38. Following the completion of the transaction, the executive vice president now owns 35,319 shares of the company’s stock, valued at approximately $3,179,416.38. This trade represents a 10.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 29,989 shares of company stock valued at $2,702,261 over the last three months. 0.50% of the stock is currently owned by insiders.

Boston Scientific Stock Down 0.8 %

Boston Scientific stock opened at $95.14 on Friday. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $140.22 billion, a P/E ratio of 78.63, a P/E/G ratio of 2.67 and a beta of 0.80. The firm has a 50 day moving average price of $89.96 and a 200-day moving average price of $83.80. Boston Scientific Co. has a twelve month low of $59.39 and a twelve month high of $97.13.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.04. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The business had revenue of $4.21 billion during the quarter, compared to the consensus estimate of $4.04 billion. During the same period last year, the business posted $0.50 earnings per share. The business’s revenue for the quarter was up 19.3% on a year-over-year basis. As a group, equities analysts predict that Boston Scientific Co. will post 2.46 EPS for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.